论文部分内容阅读
目的 :探讨可影响乳腺癌骨转移患者预后的因素。方法 :对2005年1月~2006年1月期间我院收治的40例乳腺癌骨转移患者的临床资料进行回顾性研究。我们对这40例患者的年龄、癌灶的病理检查结果、大小以及其是否进行放疗、进行的放疗是否规范、癌灶是否发生了内脏转移等情况进行统计分析,并对所有患者进行了随访,随访的时间截止2012年1月。结果 :截止2012年1月,这40例患者中有28例患者死亡。他们平均的存活时间为33.2±5.2个月。他们中存在癌灶单纯性骨转移的患者其平均的存活时间为60.2±3.3个月,存在癌灶骨转移和内脏转移的患者其平均的存活时间为13.1±4.4个月,存在癌灶骨转移和脑转移的患者其平均的存活时间为11.0±1.2个月。可影响这40例乳腺癌骨转移患者预后的因素主要包括:乳腺癌属于浸润性导管癌、乳腺癌癌灶的大小在2~5厘米之间、乳腺癌的组织分型为2型、乳腺癌的分子分型为Luminal A型、患者进行的放疗不规范、乳腺癌存在内脏转移和脑转移等。结论 :在临床上,可影响乳腺癌骨转移患者预后的因素有很多。临床医生应对这些因素加以注意,以改善乳腺癌骨转移患者的预后,延长其生存时间。
Objective: To explore the factors that affect the prognosis of breast cancer patients with bone metastases. Methods: The clinical data of 40 patients with breast cancer with bone metastasis admitted in our hospital from January 2005 to January 2006 were retrospectively studied. We conducted a statistical analysis on the age of 40 patients, the pathological findings of the foci and the size of the foci, whether or not they were treated with radiotherapy, whether the radiotherapy was performed, whether there was visceral metastasis in the foci, and all the patients were followed up, Follow-up is scheduled for January 2012. Results: As of January 2012, 28 of these 40 patients died. Their average survival time was 33.2 ± 5.2 months. The average survival time was 60.2 ± 3.3 months in patients with simple bone metastasis of cancer and 13.1 ± 4.4 months in patients with metastasis of bone and visceral metastasis, And brain metastases, the mean survival time was 11.0 ± 1.2 months. Factors affecting the prognosis of these 40 cases of breast cancer patients with bone metastases include: breast cancer is invasive ductal carcinoma, the size of breast cancer foci between 2 to 5 cm, breast cancer tissue type 2, breast cancer The molecular typing of Luminal A type, the patient’s radiotherapy is not standardized, there is visceral metastasis of breast cancer and brain metastases. CONCLUSION: There are many clinical factors that can affect the prognosis of patients with breast cancer with bone metastases. Clinicians should pay attention to these factors in order to improve the prognosis of breast cancer patients with bone metastases and prolong their survival time.